GlobeNewswire

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
30/04/2026
ALACHUA, Fla. and TAMPA, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, [...]
BioStem Strengthens Leadership Team with Appointment of Katherine Gorrell as Chief Legal & Compliance Officer
30/04/2026
Adds accomplished legal and compliance executive with two decades of experience advising healthcare organizations through complex regulatory, governance, and growth initiatives POMPANO BEACH, Fla., April 30, 2026 (GLOBE [...]
Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility
30/04/2026
At one-year mark, company has progressed all components of US investment plan to support delivery of innovative medicines to US patients New active pharmaceutical ingredients facility in North Carolina to enable end‑to‑ [...]
Indivior Reports First Quarter 2026 Financial Results and Raises Full-Year 2026 Guidance
30/04/2026
Q1’26 Total Net Revenue of $317 Million, Up 19% YoY Q1’26 Total SUBLOCADE® Net Revenue of $232 Million, Up 32% YoY Q1'26 GAAP Net Income of $89 Million and Q1'26 Non-GAAP Net Income of $123 Million Record Quarterly [...]
LENSAR® to Report First Quarter 2026 Results on May 8, 2026
30/04/2026
ORLANDO, Fla., April 30, 2026 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or the “Company”), a global medical technology company focused on advanced robotic laser solutions for the treatment of cataracts, [...]
Sangamo Therapeutics to Present Pipeline and Technology Advances at the 29th Annual Meeting of The American Society of Gene & Cell Therapy (ASGCT)
30/04/2026
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has accepted three [...]
ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors
30/04/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies [...]
Krystal Biotech to Present at Upcoming Scientific Conferences
30/04/2026
PITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held [...]
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
30/04/2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc . (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and [...]
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
30/04/2026
THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday, May 7, 2026, prior to [...]
Picard Medical / SynCardia Recognizes Banner Health as Global Leader and Supporter in the Advancement of Total Artificial Heart Technology
30/04/2026
Banner Health has performed more than 50 SynCardia Total Artificial Heart implants, establishing itself as a leading center in total artificial heart therapy TUCSON, Ariz., April 30, 2026 (GLOBE NEWSWIRE) -- Picard [...]
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
30/04/2026
ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the launch of BioReference [...]
Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy
30/04/2026
- Solid Biosciences delivers its largest scientific program at the 2026 ASGCT Annual Meeting with 5 oral presentations and 11 posters - CHARLESTOWN, Mass., April 30, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. ( [...]
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
30/04/2026
Designation granted under Innovative Licensing and Access Pathway which aims to accelerate development of, and access to, transformative new medicines in the United Kingdom LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- [...]
EUROAPI_Liquidity Contract
30/04/2026
Press Release Paris 30 avril, 2026 Share buyback program Reduction in the Resources Allocated under the Liquidity Contract with Kepler Cheuvreux By agreement dated 30 May 2022, EUROAPI (ISIN: FR0014008VX5) entrusted [...]
EUROAPI_Contrat de liquidité
30/04/2026
Communiqué de presse Paris, 30 avril 2026 Programme de rachat d’actions Réduction de moyen au contrat de liquidité avec Kepler Cheuvreux Par contrat en date du 30 mai 2022, la société EUROAPI (ISIN: FR0014008VX5) a [...]
OSE Immunotherapeutics Reports Full Year 2025 Unaudited Consolidated Financial Results and 2026 Q1 Cash Position
30/04/2026
OSE entered 2026 with a clear 3-year strategic roadmap focused on delivering multiple catalysts for both lusvertikimab and Tedopi® 1 €22.7 and €17.0 million cash position as of December 31, 2025, and March 31, 2026, [...]
OSE Immunotherapeutics publie ses résultats financiers consolidés non audités pour l’exercice 2025 et sa situation de trésorerie du 1er trimestre 2026
30/04/2026
OSE a abordé 2026 avec un plan stratégique clair à 3 ans, axé sur plusieurs catalyseurs à court terme pour lusvertikimab et Tedopi® 1 Trésorerie de 22,7 millions d’euros au 31 décembre 2025 et 17,0 millions d’euros au [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum